IRadimed (IRMD) Stock Forecast, Price Target & Predictions
IRMD Stock Forecast
IRadimed stock forecast is as follows: an average price target of $60.00 (represents a 9.79% upside from IRMD’s last price of $54.65) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
IRMD Price Target
The average price target for IRadimed (IRMD) is $60.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $60.00 to $60.00. This represents a potential 9.79% upside from IRMD's last price of $54.65.
IRMD Analyst Ratings
According to 1 Wall Street analysts, IRadimed's rating consensus is 'Buy'. The analyst rating breakdown for IRMD stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
IRadimed Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 02, 2024 | Jason Wittes | Roth Capital | $60.00 | $46.15 | 30.01% | 9.79% |
| Jun 17, 2024 | Frank Takkinen | Loop Capital Markets | $60.00 | $43.28 | 38.62% | 9.79% |
The latest IRadimed stock forecast, released on Aug 02, 2024 by Jason Wittes from Roth Capital, set a price target of $60.00, which represents a 30.01% increase from the stock price at the time of the forecast ($46.15), and a 9.79% increase from IRMD last price ($54.65).
IRadimed Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $60.00 |
| Last Closing Price | $54.65 | $54.65 | $54.65 |
| Upside/Downside | -100.00% | -100.00% | 9.79% |
In the current month, the average price target of IRadimed stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to IRadimed's last price of $54.65. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 17, 2024 | Lake Street | Buy | Buy | Hold |
IRadimed's last stock rating was published by Lake Street on Jun 17, 2024. The company gave IRMD a "Buy" rating, the same as its previous rate.
IRadimed Financial Forecast
IRadimed Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $17.45M | $16.50M | $16.13M | $15.48M | $14.86M | $13.41M | $12.72M | $12.31M | $11.87M | $10.91M | $9.81M | $9.22M | $8.55M | $7.70M | $6.79M | $8.68M | $10.89M | $9.96M | $9.23M | $8.44M | $7.11M | $5.16M |
| Avg Forecast | $20.96M | $20.55M | $20.01M | $19.13M | $18.94M | $18.15M | $17.65M | $17.15M | $17.30M | $16.18M | $15.66M | $14.77M | $14.90M | $13.19M | $12.60M | $12.21M | $11.65M | $10.40M | $8.46M | $8.56M | $8.44M | $8.21M | $6.44M | $9.66M | $10.92M | $9.79M | $8.91M | $8.44M | $5.86M | $18.59M |
| High Forecast | $21.14M | $20.72M | $20.17M | $19.29M | $19.10M | $18.18M | $17.80M | $17.29M | $17.44M | $16.23M | $15.79M | $14.89M | $15.02M | $13.19M | $12.60M | $12.21M | $11.65M | $10.40M | $8.46M | $8.56M | $8.44M | $8.21M | $6.44M | $9.66M | $10.92M | $9.79M | $8.91M | $8.44M | $7.04M | $22.30M |
| Low Forecast | $20.79M | $20.38M | $19.84M | $18.97M | $18.79M | $18.12M | $17.50M | $17.01M | $17.16M | $16.10M | $15.53M | $14.64M | $14.78M | $13.19M | $12.60M | $12.21M | $11.65M | $10.40M | $8.46M | $8.56M | $8.44M | $8.21M | $6.44M | $9.66M | $10.92M | $9.79M | $8.91M | $8.44M | $4.69M | $14.87M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 14 |
| Surprise % | - | - | - | - | - | - | - | - | 1.01% | 1.02% | 1.03% | 1.05% | 1.00% | 1.02% | 1.01% | 1.01% | 1.02% | 1.05% | 1.16% | 1.08% | 1.01% | 0.94% | 1.06% | 0.90% | 1.00% | 1.02% | 1.04% | 1.00% | 1.21% | 0.28% |
IRadimed's average Quarter revenue forecast for Mar 24 based on 1 analysts is $17.15M, with a low forecast of $17.01M, and a high forecast of $17.29M. IRMD's average Quarter revenue forecast represents a -1.73% decrease compared to the company's last Quarter revenue of $17.45M (Dec 23).
IRadimed EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 14 |
| EBITDA | - | - | - | - | - | - | - | - | $5.16M | $5.91M | $4.96M | $4.19M | $4.25M | $4.57M | $4.66M | $3.51M | $3.50M | $3.43M | $2.21M | $2.10M | $1.00M | $1.13M | $-2.59M | $1.18M | $2.63M | $2.92M | $2.74M | $1.99M | $1.56M | $-124.79K |
| Avg Forecast | $4.89M | $4.80M | $4.67M | $4.46M | $4.42M | $4.23M | $4.12M | $4.03M | $4.04M | $3.77M | $3.65M | $3.66M | $1.82M | $3.04M | $2.91M | $3.33M | $2.69M | $2.40M | $1.95M | $1.47M | $1.95M | $1.90M | $1.49M | $944.42K | $2.52M | $2.26M | $2.06M | $2.26M | $1.23M | $-449.24K |
| High Forecast | $4.93M | $4.84M | $4.71M | $4.50M | $4.46M | $4.24M | $4.15M | $4.83M | $4.07M | $3.79M | $3.68M | $4.39M | $2.18M | $3.04M | $2.91M | $3.99M | $2.69M | $2.40M | $1.95M | $1.77M | $1.95M | $1.90M | $1.49M | $1.13M | $2.52M | $2.26M | $2.06M | $2.71M | $1.47M | $-359.39K |
| Low Forecast | $4.85M | $4.76M | $4.63M | $4.43M | $4.38M | $4.23M | $4.08M | $3.22M | $4.00M | $3.76M | $3.62M | $2.93M | $1.45M | $3.04M | $2.91M | $2.66M | $2.69M | $2.40M | $1.95M | $1.18M | $1.95M | $1.90M | $1.49M | $755.53K | $2.52M | $2.26M | $2.06M | $1.81M | $980.21K | $-539.08K |
| Surprise % | - | - | - | - | - | - | - | - | 1.28% | 1.56% | 1.36% | 1.14% | 2.34% | 1.50% | 1.60% | 1.05% | 1.30% | 1.43% | 1.13% | 1.43% | 0.52% | 0.59% | -1.74% | 1.25% | 1.05% | 1.29% | 1.33% | 0.88% | 1.27% | 0.28% |
1 analysts predict IRMD's average Quarter EBITDA for Mar 24 to be $4.03M, with a high of $4.83M and a low of $3.22M. This is -21.97% lower than IRadimed's previous annual EBITDA (Dec 23) of $5.16M.
IRadimed Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 14 |
| Net Income | - | - | - | - | - | - | - | - | $4.54M | $5.07M | $4.18M | $3.41M | $3.67M | $3.43M | $3.24M | $2.49M | $3.89M | $2.58M | $1.47M | $1.39M | $637.41K | $1.07M | $-2.11M | $1.77M | $3.24M | $2.45M | $2.09M | $1.85M | $841.20K | $-233.34K |
| Avg Forecast | $5.81M | $5.75M | $5.56M | $5.24M | $5.56M | $5.18M | $4.66M | $2.87M | $4.86M | $4.64M | $3.96M | $2.61M | $2.02M | $3.13M | $3.00M | $2.37M | $2.49M | $2.17M | $1.21M | $970.79K | $1.34M | $1.28M | $-63.79K | $1.42M | $2.62M | $1.98M | $1.91M | $2.09M | $662.76K | $-840.02K |
| High Forecast | $5.88M | $5.81M | $5.62M | $5.30M | $5.62M | $5.30M | $4.71M | $3.44M | $4.99M | $4.77M | $4.00M | $3.13M | $2.42M | $3.13M | $3.00M | $2.84M | $2.49M | $2.17M | $1.21M | $1.16M | $1.34M | $1.28M | $-63.79K | $1.70M | $2.62M | $1.98M | $1.91M | $2.51M | $795.31K | $-672.02K |
| Low Forecast | $5.75M | $5.69M | $5.50M | $5.18M | $5.50M | $5.05M | $4.61M | $2.29M | $4.59M | $4.59M | $3.92M | $2.08M | $1.61M | $3.13M | $3.00M | $1.89M | $2.49M | $2.17M | $1.21M | $776.63K | $1.34M | $1.28M | $-63.79K | $1.13M | $2.62M | $1.98M | $1.91M | $1.67M | $530.21K | $-1.01M |
| Surprise % | - | - | - | - | - | - | - | - | 0.93% | 1.09% | 1.06% | 1.31% | 1.82% | 1.10% | 1.08% | 1.05% | 1.56% | 1.19% | 1.21% | 1.43% | 0.48% | 0.84% | 33.11% | 1.25% | 1.24% | 1.24% | 1.09% | 0.88% | 1.27% | 0.28% |
IRadimed's average Quarter net income forecast for Mar 24 is $2.87M, with a range of $2.29M to $3.44M. IRMD's average Quarter net income forecast represents a -36.88% decrease compared to the company's last Quarter net income of $4.54M (Dec 23).
IRadimed SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 14 |
| SG&A | - | - | - | - | - | - | - | - | $7.60M | $6.48M | $6.26M | $6.92M | $6.36M | $5.92M | $5.31M | $5.79M | $5.65M | $4.84M | $5.03M | $4.81M | $5.28M | $4.48M | $7.38M | $5.30M | $5.53M | $4.91M | $4.66M | $4.52M | $3.95M | $3.47M |
| Avg Forecast | $10.72M | $10.51M | $10.23M | $9.78M | $9.69M | $9.28M | $9.03M | $6.67M | $8.85M | $8.27M | $8.01M | $6.06M | $2.93M | $6.74M | $6.44M | $5.51M | $5.96M | $5.32M | $4.33M | $3.37M | $4.32M | $4.20M | $3.29M | $4.24M | $5.58M | $5.00M | $4.56M | $5.13M | $3.11M | $12.50M |
| High Forecast | $10.81M | $10.60M | $10.32M | $9.87M | $9.77M | $9.30M | $9.10M | $8.00M | $8.92M | $8.30M | $8.07M | $7.27M | $3.51M | $6.74M | $6.44M | $6.61M | $5.96M | $5.32M | $4.33M | $4.04M | $4.32M | $4.20M | $3.29M | $5.08M | $5.58M | $5.00M | $4.56M | $6.15M | $3.73M | $15.00M |
| Low Forecast | $10.63M | $10.42M | $10.15M | $9.70M | $9.61M | $9.27M | $8.95M | $5.33M | $8.77M | $8.24M | $7.94M | $4.85M | $2.34M | $6.74M | $6.44M | $4.41M | $5.96M | $5.32M | $4.33M | $2.69M | $4.32M | $4.20M | $3.29M | $3.39M | $5.58M | $5.00M | $4.56M | $4.10M | $2.49M | $10.00M |
| Surprise % | - | - | - | - | - | - | - | - | 0.86% | 0.78% | 0.78% | 1.14% | 2.17% | 0.88% | 0.82% | 1.05% | 0.95% | 0.91% | 1.16% | 1.43% | 1.22% | 1.07% | 2.24% | 1.25% | 0.99% | 0.98% | 1.02% | 0.88% | 1.27% | 0.28% |
IRadimed's average Quarter SG&A projection for Mar 24 is $6.67M, based on 1 Wall Street analysts, with a range of $5.33M to $8.00M. The forecast indicates a -12.31% fall compared to IRMD last annual SG&A of $7.60M (Dec 23).
IRadimed EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 5 | 4 | 4 | 3 | 4 | 3 | 8 | 14 |
| EPS | - | - | - | - | - | - | - | - | $0.36 | $0.40 | $0.33 | $0.27 | $0.29 | $0.27 | $0.26 | $0.20 | $0.31 | $0.21 | $0.12 | $0.11 | $0.05 | $0.09 | $-0.17 | $0.15 | $0.28 | $0.22 | $0.19 | $0.17 | $0.08 | $-0.02 |
| Avg Forecast | $0.46 | $0.45 | $0.43 | $0.41 | $0.43 | $0.41 | $0.36 | $0.34 | $0.38 | $0.36 | $0.31 | $0.28 | $0.30 | $0.24 | $0.23 | $0.21 | $0.20 | $0.17 | $0.10 | $0.10 | $0.10 | $0.10 | $-0.01 | $0.15 | $0.20 | $0.15 | $0.15 | $0.13 | $0.05 | $0.04 |
| High Forecast | $0.46 | $0.45 | $0.44 | $0.41 | $0.44 | $0.41 | $0.37 | $0.34 | $0.39 | $0.37 | $0.31 | $0.29 | $0.30 | $0.24 | $0.23 | $0.21 | $0.20 | $0.17 | $0.10 | $0.10 | $0.10 | $0.10 | $-0.01 | $0.15 | $0.20 | $0.15 | $0.15 | $0.13 | $0.06 | $0.04 |
| Low Forecast | $0.45 | $0.45 | $0.43 | $0.41 | $0.43 | $0.40 | $0.36 | $0.33 | $0.36 | $0.36 | $0.31 | $0.28 | $0.30 | $0.24 | $0.23 | $0.21 | $0.20 | $0.17 | $0.10 | $0.10 | $0.10 | $0.10 | $-0.01 | $0.15 | $0.20 | $0.15 | $0.15 | $0.13 | $0.04 | $0.03 |
| Surprise % | - | - | - | - | - | - | - | - | 0.95% | 1.10% | 1.06% | 0.95% | 0.97% | 1.10% | 1.11% | 0.95% | 1.59% | 1.24% | 1.26% | 1.10% | 0.48% | 0.90% | 34.00% | 1.00% | 1.37% | 1.42% | 1.27% | 1.31% | 1.60% | -0.50% |
According to 1 Wall Street analysts, IRadimed's projected average Quarter EPS for Mar 24 is $0.34, with a low estimate of $0.33 and a high estimate of $0.34. This represents a -6.94% decrease compared to IRMD previous annual EPS of $0.36 (Dec 23).
IRadimed Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LUNG | Pulmonx | $6.13 | $13.00 | 112.07% | Buy |
| SGHT | Sight Sciences | $3.62 | $7.50 | 107.18% | Hold |
| KIDS | OrthoPediatrics | $22.46 | $39.50 | 75.87% | Buy |
| LIVN | LivaNova | $49.94 | $68.25 | 36.66% | Buy |
| CNMD | CONMED | $71.23 | $97.00 | 36.18% | Buy |
| OFIX | Orthofix Medical | $17.93 | $24.00 | 33.85% | |
| NPCE | NeuroPace | $11.52 | $15.00 | 30.21% | Buy |
| IRMD | IRadimed | $53.00 | $60.00 | 13.21% | Buy |
| ITGR | Integer | $136.68 | $153.50 | 12.31% | Buy |
| SRDX | Surmodics | $39.96 | $39.50 | -1.15% | Buy |
| GKOS | Glaukos | $146.35 | $144.14 | -1.51% | Buy |